Needham Maintains Buy on Immix Biopharma, Raises Price Target to $30

Needham analyst Gil Blum has maintained a Buy rating on Immix Biopharma (NASDAQ: IMMX) and raised the price target from $21 to $30. This adjustment reflects an optimistic outlook for the company's performance in the market.